Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MANN, J. D.
Right arrow Articles by CAMPA, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MANN, J. D.
Right arrow Articles by CAMPA, J. F.
NEUROLOGY 1976;26:729
© 1976 American Academy of Neurology

Long-term administration of corticosteroids in myasthenia gravis

J. DOUGLAS MANN, M.D., T. R. JOHNS, M.D. and JUSTINIANO F. CAMPA, M.D., Ph.D.

From the Department of Neurology, University of Virginia Medical Center, Charlottesville.

Favorable results were obtained in 30 patients with myasthenia gravis treated initially with high daily doses of prednisone and subsequently maintained on lower doses for a protracted period. In 45 incidents of treatment, complete remission occurred in 69 percent, marked improvement in 20 percent, and moderate improvement in 7 percent. Nineteen patients proceeded to thymectomy, with negligible morbidity and sustained improvement. In four patients, it was possible to discontinue prednisone 1 year or more after thymectomy.

Requests for reprints should be addressed to Dr. Johns, Department of Neurology, University of Virginia Medical Center, Charlottesville, VA22901.

This study was supported in part by NINCDS training grant NB-5120 and Muscular Dystrophy Associations of America, Inc., and the Clinical Research Unit was supported by USPHS grant No. RR847.

Presented in part at the twenty-fourth annual meeting of the American Academy of Neurology, St. Louis, April 1972.

Received for publication August 26, 1975.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
M. J. Kupersmith, M. Moster, S. Bhuiyan, F. Warren, and H. Weinberg
Beneficial Effects of Corticosteroids on Ocular Myasthenia Gravis
Arch Neurol, August 1, 1996; 53(8): 802 - 804.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
E. Arsura, N. G. Brunner, T. Namba, and D. Grob
High-Dose Intravenous Methylprednisolone in Myasthenia Gravis
Arch Neurol, December 1, 1985; 42(12): 1149 - 1153.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
W. F. Collins Jr, R. O. Burns Jr, T. R. Johns, D. G. Kline, P. W. Myers, and G. R. Nugent
Common Neuromuscular Disorders and Injuries to the Peripheral and Cranial Nerves and Spinal Cord--Panel 5
Arch Neurol, November 1, 1979; 36(12): 771 - 781.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
Y. Harati and B. M. Patten
Prednisone Use in Concurrent Autoimmune Diseases: Treatment of a Patient With Myasthenia Gravis, Hyperthyroidism, and Polymyositis
Arch Neurol, February 1, 1979; 36(2): 103 - 106.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
D. B. Sanders, T. R. Johns, M. E. Eldefrawi, and E. E. Cobb
Experimental Autoimmune Myasthenia Gravis in Rats: Modification by Thymectomy and Prednisolone
Arch Neurol, February 1, 1977; 34(2): 75 - 79.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by AAN Enterprises, Inc.